Studies reveal new benefits of Peptan in preventing osteoporosis

Studies Conducted at INRA-Agroparistech Laboratory Under Pr. Daniel Tome's Supervision and Published in November 2009, in the Official Journal of the International Bone and Mineral Society "Bone", Reveal new Benefits for Peptan(TM) in Osteoporosis Prevention

In response to consumer concerns regarding long-term bone health, Rousselot has carried out, for several years now, many studies to demonstrate that an oral intake of Peptan(TM) may have a positive impact on osteoporosis.

Bone is a living dynamic metabolic system that relies on a maintained balance between bone formation and bone resorption. Cells called osteoblasts make bone while cells called osteoclasts resorb it. An imbalance may lead to osteoporosis, a condition where the density and quality of bone is reduced.

Researchers conducted in vitro studies, and highlighted that Peptan(TM) in bone cell culture induced a better differentiation of osteoblasts. Those positive results have then been confirmed in vivo on ovariectomized mice, used to simulate a postmenopausal osteoporosis, which leads to a lower bone mineral density (BMD).

Animals were divided into three groups: a control group (non ovariectomized), a group of ovariectomized mice, both fed with a normal diet and a group of ovariectomized mice that received a diet containing Peptan(TM). After 12 weeks, the BMD of the group fed with Peptan(TM) is not significantly different from the BMD of control group. On the contrary the BMD of ovariectomized mice not fed with Peptan(TM) is lower.

Confirmation of Peptan(TM) benefits on bone health has been obtained by the measures of Carboxy Terminal Telopeptide (CTX), a usual marker of bone resorption. CTX is significantly lower in mice fed with Peptan(TM) indicating that bone resorption is reduced.

Researchers conclude that Peptan(TM) may restore bone density in simulated post-menopausal osteoporosis by stimulating osteoblast growth and differentiation. This demonstrates the interest of Peptan(TM) as a bioactive ingredient to help preventing bone loss during aging.

Source:

ROUSSELOT SAS

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Osteoporosis model rats show improved healing with FGF-2 treatment